BACKGROUND: Hypericin, the active compound in St. John's Wort, has antiretroviral activity in vitro. Many HIV-infected persons use St. John's wort. OBJECTIVE: To evaluate the safety and antiretroviral activity of hypericin in HIV-infected patients. DESIGN: Phase I study. SETTING: Four clinical research units. PATIENTS: 30 HIV-infected patients with CD4 counts less than 350 cells/mm3. INTERVENTION: Intravenous hypericin, 0.25 or 0.5 mg/kg of body weight twice weekly or 0.25 mg/kg three times weekly, or oral hypericin, 0.5 mg/kg daily. MEASUREMENTS: Safety was assessed at weekly visits. Antiretroviral activity was assessed by changes in HIV p24 antigen level, HIV titer, HIV RNA copies, and CD4 cell counts. RESULTS: Of the 30 patients who were enrolled, 16 discontinued treatment early because of toxic effects. Severe cutaneous phototoxicity was observed in 11 of 23 (48% [95% CI, 27% to 69%]) evaluable patients, and dose escalation could not be completed. Virologic markers and CD4 cell count did not significantly change. CONCLUSIONS: Hypericin caused significant phototoxicity and had no antiretroviral activity in the limited number of patients studied.
BACKGROUND:Hypericin, the active compound in St. John's Wort, has antiretroviral activity in vitro. Many HIV-infectedpersons use St. John's wort. OBJECTIVE: To evaluate the safety and antiretroviral activity of hypericin in HIV-infectedpatients. DESIGN: Phase I study. SETTING: Four clinical research units. PATIENTS: 30 HIV-infectedpatients with CD4 counts less than 350 cells/mm3. INTERVENTION: Intravenous hypericin, 0.25 or 0.5 mg/kg of body weight twice weekly or 0.25 mg/kg three times weekly, or oral hypericin, 0.5 mg/kg daily. MEASUREMENTS: Safety was assessed at weekly visits. Antiretroviral activity was assessed by changes in HIVp24 antigen level, HIV titer, HIV RNA copies, and CD4 cell counts. RESULTS: Of the 30 patients who were enrolled, 16 discontinued treatment early because of toxic effects. Severe cutaneous phototoxicity was observed in 11 of 23 (48% [95% CI, 27% to 69%]) evaluable patients, and dose escalation could not be completed. Virologic markers and CD4 cell count did not significantly change. CONCLUSIONS:Hypericin caused significant phototoxicity and had no antiretroviral activity in the limited number of patients studied.
Authors: Albert R Wielgus; Colin F Chignell; David S Miller; Ben Van Houten; Joel Meyer; Dan-Ning Hu; Joan E Roberts Journal: Photochem Photobiol Date: 2007 May-Jun Impact factor: 3.421
Authors: J M Jacobson; L Feinman; L Liebes; N Ostrow; V Koslowski; A Tobia; B E Cabana; D Lee; J Spritzler; A M Prince Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191
Authors: Laura A Schmitt; Yi Liu; Patricia A Murphy; Jacob W Petrich; Philip M Dixon; Diane F Birt Journal: J Photochem Photobiol B Date: 2006-07-21 Impact factor: 6.252
Authors: Wendy Maury; Jason P Price; Melinda A Brindley; ChoonSeok Oh; Jeffrey D Neighbors; David F Wiemer; Nickolas Wills; Susan Carpenter; Cathy Hauck; Patricia Murphy; Mark P Widrlechner; Kathleen Delate; Ganesh Kumar; George A Kraus; Ludmila Rizshsky; Basil Nikolau Journal: Virol J Date: 2009-07-13 Impact factor: 4.099
Authors: Andreas Johne; Elke S Perloff; Steffen Bauer; Jürgen Schmider; Ingrid Mai; Jürgen Brockmöller; Ivar Roots Journal: Eur J Clin Pharmacol Date: 2004-09-15 Impact factor: 2.953
Authors: Jace A Willis; Vsevolod Cheburkanov; Giulia Kassab; Jennifer M Soares; Kate C Blanco; Vanderlei S Bagnato; Vladislav V Yakovlev Journal: Appl Phys Rev Date: 2021-06 Impact factor: 19.162